All In Biotech

NDA 021419 · Specgx LLC

Methylin

Methylphenidate Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Oct 13, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2002

Dec 19, 2002

Approved uses

1

Original approval plus efficacy supplements

Registered trials

456

101 Phase 3, 37 recruiting

FAERS reports

7,558

4,673 serious, 508 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ABUSE, MISUSE, AND ADDICTION Methylin has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including Methylin, can result in overdose and death [see Overdosage ( 10 )] , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing Methylin, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout Methylin treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction [see Warnings and Precautions ( 5.1 ) and Drug Abuse and Dependence ( 9.2 )] . WARNING: ABUSE, MISUSE, AND...

What it is approved for

From the label in effect Nov 1, 2023.

Methylin is indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years of age and older Narcolepsy Methylin is a central nervous system (CNS) stimulant indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years of age and older ( 1 ) Narcolepsy ( 1 )

Mechanism: Methylphenidate hydrochloride is a central nervous system (CNS) stimulant. The mode of therapeutic action in ADHD is not known.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • METHYLIN · METHYLPHENIDATE HYDROCHLORIDE 5MG/5ML · SOLUTION, ORAL · Prescription · TE AA
  • METHYLIN · METHYLPHENIDATE HYDROCHLORIDE 10MG/5ML · SOLUTION, ORAL · Prescription · TE AA

Clinical trials

Interventional ClinicalTrials.gov studies with "Methylphenidate" as an intervention, any sponsor and status, largest first.

All 456 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,100
  • headache416
  • fatigue384
  • anxiety381
  • off label use376
  • nausea355
  • toxicity to various agents343
  • drug abuse307
  • product substitution issue296
  • somnolence285
  • insomnia281
  • disturbance in attention256

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20046
20057
20065
200715
200823
200973
201082
201155
2012128
2013151
2014149
2015484
2016422
2017532
2018604
2019480
2020361
2021412
2022615
2023796
2024748
2025729
2026681

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Methylin (Methylphenidate HCl)

2024 spending

$3K

Beneficiaries

n/a

31 claims

Per beneficiary

n/a

$0.16 per unit

View as table
YearSpending
2020$0
2021$1,966
2022$2,538
2023$3,950
2024$2,773

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,058 on PubMed

Sponsor: Specgx LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.